Free tools Windows power users keep installed
One-click scans. No signup required.
Digital Biotechnologies, a Seattle-based subsidiary created by Adaptive Biotechnologies, completed an approximately $15 million Series A financing through February 2026. The company is developing an early-stage clinical DNA-sequencing instrument described as solid-state and aimed at combining accuracy, speed, and lower cost. Adaptive remains a major shareholder and continues to consolidate Digital Biotechnologies’ results, so this is a separately financed subsidiary—not a fully independent spin-off.
What happened with Digital Biotechnologies’ financing?
The financing was initially disclosed as a Series A that could total up to $15 million. In a December 30, 2025 Form 8-K, Adaptive Biotechnologies said Digital Biotechnologies had completed an initial closing and anticipated total proceeds of up to $15 million.
As an Amazon Associate I earn from qualifying purchases.
Adaptive’s later proxy statement provides the updated picture: Digital Biotechnologies completed the Series A through multiple closings from December 2025 through February 2026, raising approximately $15 million in total. The current description should therefore be “raised approximately $15 million,” rather than “is raising $15 million.”
This was financing for Adaptive’s subsidiary, not a new corporate fundraising round by Adaptive Biotechnologies itself.
#1 Best Overall
- REVIEW IMPORTANT TEST INFO AND ELIGIBILITY: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk*, Carrier Status*, and Pharmacogenetics** reports at 23andme. org/test-info and 23andme. org/test-info/pharmacogenetics. To be eligible for Total Health, you must be 18 years or older and live in the US — excluding AL, GA, HI, LA, MS, NJ, NY, PR, RI, SC, TN, and US territories (due to state and regional restrictions). You must not have received a blood transfusion in the last 30 days or a bone marrow transplant.
- ACCESS CLINICAL-GRADE EXOME SEQUENCING: Go beyond standard DNA genotyping. Clinical-grade Exome Sequencing analyzes analyzes a portion of your total DNA, detecting 200x more disease-causing variants than genotyping.Δ Valid payment method required at kit registration.
- TRACK 55+ BIOMARKERS TWICE A YEAR: Track your health progression with twice-yearly lab blood testing. Evaluate 55+ cardiometabolic biomarkers, calculate your Biological Age, and discover how your DNA could influence weight loss and nausea on GLP-1 medications.
- REVIEW RESULTS WITH A GENETICS-TRAINED CLINICIAN: Meet virtually with clinicians trained in genetics-informed care, message your care team with questions, and get a personalized preventive care plan to discuss next steps.
- INCLUDES EVERYTHING IN PREMIUM ANCESTRY + HEALTH: Get DNA insights on Condition*, Carrier Status*, Pharmacogenetics how your body processes certain medications**), and Wellness. Access preventive health features like Health Tracks(SM) and advanced ancestry features like Historical Matches(R), Reconstructed Ancestors, and up to 5,000 DNA Relatives.
What is Digital Biotechnologies?
Digital Biotechnologies was formed in 2021 under the name Spin Technologies Inc. Adaptive renamed it Digital Biotechnologies in February 2022. Adaptive contributed a patent license in exchange for 7 million common shares, representing a 70% ownership interest at formation.
The company operated from Adaptive’s Seattle headquarters and developed a sequencing project that Adaptive described as ancillary to its main focus. Adaptive’s filings sometimes refer to the business as “DigitalBio.” Public information about its team and operations remains limited. GeekWire identified Jason Bielas, who is associated with the University of Washington and Fred Hutch Cancer Center, as a co-founder.
The Series A represents a financing and autonomy milestone for an existing internal project, rather than the creation of an entirely new company in late 2025.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →What technology is it developing?
The public description points to a hardware-oriented DNA-sequencing instrument for clinical applications. A Digital Biotechnologies job posting described the proposed platform as a solid-state sequencer. Adaptive and related coverage have emphasized three intended attributes:
Rank #2
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600+ places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- DNA + TRAITS: Ever wondered where your freckles came from, or why you hate cilantro? AncestryDNA + Traits lets you discover 75+ genetic traits, allowing you to explore how your genes might have influenced a range of appearance, sensory, performance, nutrient, and other personal characteristics.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA is the only DNA test that can show your origins results, DNA matches, and traits by each side of the family, without your parents taking a DNA test.
- high accuracy;
- rapid turnaround; and
- lower cost.
Adaptive has also described the broader goal as faster and more cost-effective point-of-care diagnostic DNA testing. That is a stated target application, not evidence that a point-of-care product currently exists.
“Solid-state” describes an architectural direction, not a complete technical specification. The available information does not identify the sequencing chemistry, sensor, read technology, throughput, read length, error rate, limit of detection, or sample-preparation workflow. It would be premature to infer that the platform uses nanopore, semiconductor, optical-free, or any other particular approach.
Why did Adaptive create a separate company?
Adaptive’s core commercial activities center on immune-system analysis, immune-receptor sequencing, and minimal residual disease testing. Its clonoSEQ product is particularly associated with MRD testing. Digital Biotechnologies is not described as a new clonoSEQ product or as a direct replacement for that assay.
Adaptive has characterized DigitalBio as adjacent to, but not core to, its focus on immune medicine and MRD. A separate company can give the sequencing project a dedicated engineering and product organization while allowing Adaptive to retain an economic and strategic interest. External financing can also provide capital and operational autonomy without placing the entire development program on Adaptive’s primary commercial roadmap.
Rank #3
- REVIEW IMPORTANT TEST INFO: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk*, Carrier Status*, and Pharmacogenetics** reports at 23andme. org/test-info and 23andme. org/test-info/pharmacogenetics. A portion of your purchase may be eligible for FSA/HSA reimbursement***.
- UNDERSTAND YOUR GENETIC HEALTH: Receive 160+ personalized genetic reports, including 50+ Conditions* and wellness reports. Get insights into heart health, metabolic health, mental health, and more. You choose whether to view certain reports.
- TRACK HEALTH GOALS: Health Tracks(SM) show how everyday choices may shape your health over time. Opt in to the Family Health History Tree to input and track information to share with your healthcare provider.
- PLAN AHEAD WITH 45+ CARRIER STATUS REPORTS*: Find out whether you carry a genetic variant for inherited conditions across categories like blood, lung, and hearing health, information you can bring to family planning conversations with your healthcare provider.
- LEARN HOW YOUR BODY MAY RESPOND: FDA-authorized pharmacogenetics reports show how your DNA may impact the way your body processes certain medications**, including some used in heart health and mental health care. Talk to your healthcare provider before making any medication changes.
The arrangement does not mean the companies are operationally unrelated. Adaptive reported providing DigitalBio with services valued at $8.3 million through December 31, 2025, including $3.3 million in share-based compensation treated as paid-in capital. The company expected to amend the shared-services agreement and reduce the accounting, human-resources, legal, information-technology, and laboratory support it provided.
How much of Digital Biotechnologies does Adaptive own?
Adaptive’s ownership declined as Digital Biotechnologies issued shares in the Series A, but Adaptive retained significant influence and control rights.
| Period | Adaptive’s reported position |
|---|---|
| Before the Series A | 70% ownership |
| Initial financing disclosure | Expected to retain nearly 50% after the financing |
| After the Series A | Nearly 50%, according to Adaptive’s proxy |
| March 31, 2026 | 46% ownership, with control rights |
Adaptive’s first-quarter 2026 filing reported a 46% ownership interest as of March 31, 2026. Despite owning less than half of the company, Adaptive continued consolidating Digital Biotechnologies’ financial results because it retained control rights.
That accounting treatment is important. “Spinout” does not necessarily mean “independent company.” Digital Biotechnologies is separately financed, but it remains closely connected to Adaptive in ownership, governance, services, and financial reporting.
Rank #4
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600 places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA provides more precise ancestral origins with greater geographic detail. Our innovative SideView technology takes your results even further by showing your origins and matches by parental side. *Some DNA features require an Ancestry subscription.
- BUILD YOUR FAMILY TREE: Combine what you learn from your DNA results with an Ancestry subscription and gain access to millions of family trees and the world's largest collection of online family history records. *Access to record collections varies depending on subscription level.
What do the related-party disclosures show?
Adaptive’s proxy provides more detail than the initial financing announcement. It says Chad Robins, Harlan Robins, Julie Rubinstein, related family trusts, and other related parties held minority interests in DigitalBio before the Series A. Certain related parties also participated in the financing.
These disclosures do not by themselves establish wrongdoing. They do, however, make governance and valuation relevant questions for investors and other readers. Important issues include how the patent license was valued, how the financing was approved, whether an independent board committee reviewed the transaction, which related parties invested, and how continuing shared services are priced and governed.
The proxy is the most useful primary source for those details: Adaptive’s 2026 proxy statement.
Why clinical sequencing is difficult
A sequencing instrument intended for clinical use must do more than produce DNA reads quickly or at a low hardware price. It must fit a complete diagnostic workflow, including:
Best Value
- DISCOVER WHAT MAKES YOUR BODY UNIQUE - Stop guessing how your body processes nutrients, produces energy, and manages everyday stress. This DNA testing kit analyzes 13 methylation genes to uncover the specific variations that may be affecting your energy, nutrient absorption, and stress response; backed by 500+ peer-reviewed studies.
- 13 METHYLATION GENES ANALYZED - Most methylation test options check just MTHFR or a handful of variants. This panel covers MTHFR, COMT, MTR & MTRR, and 10 more critical genes, a more comprehensive picture of how your body processes B-vitamins, supports detox pathways, and regulates mood-related functions.
- ACTIONABLE REPORTS, NOT RAW DATA - Go far beyond simple genetic reporting. This genetic testing kit delivers clear reports that translate complex methylation-genotype data about methylation into personalized insights and suggestions, so you know exactly what to explore next about your nutrition, energy, supplementation, and daily habits. Complimentary call with an expert included.
- SIMPLE CHEEK SWAB, FAST RESULTS - No blood draws or doctor visits. Swab, seal, and mail it back in minutes. Receive your results in 3-5 weeks, not the 2-3 months other DNA tests can take. Everything you need is in the box
- YOUR DNA DATA STAYS PRIVATE - Your genetic data is yours. Period. It is never sold to third parties, never shared with insurance companies, never accessed without your permission. You keep 100% ownership with full control, including the right to delete it anytime. Trusted by tens of thousands. This product is an informational wellness tool, not a substitute for professional healthcare guidance.
- sample collection and preparation;
- accuracy and reproducibility across instruments, operators, and sample types;
- throughput and turnaround time;
- reagent stability and cost;
- instrument maintenance and contamination control;
- bioinformatics and result interpretation;
- quality-control procedures;
- clinical validation;
- regulatory requirements; and
- laboratory integration, reimbursement, and customer support.
These variables involve trade-offs. Faster processing can create pressure on accuracy or sample preparation. Lower-cost hardware can shift expense into reagents, service contracts, computation, or labor. A compact platform may be attractive for decentralized testing but offer less throughput than a centralized laboratory system.
The phrase “clinical sequencing” also should not be read as evidence of clinical availability. A platform may be research-use-only, used in a laboratory-developed test, developed as an in-vitro diagnostic, or still be in engineering and validation. No regulatory authorization, clinical deployment, or public clinical validation data was identified in the available disclosures.
What remains unknown?
The public record does not yet establish:
- the sequencing chemistry or sensor technology;
- throughput, read length, accuracy, or error-rate specifications;
- the platform’s limit of detection;
- a named first clinical indication;
- whether a working prototype has been publicly demonstrated;
- clinical validation results;
- a regulatory submission or clearance;
- a commercial launch date;
- the platform’s total cost per test; or
- the identities and investment amounts of outside financing participants.
Accordingly, the Series A should be understood as funding for development of a clinical sequencing technology—not as evidence that a new clinical sequencing product is already available or competitive with established platforms.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What should readers watch next?
The most meaningful future milestones will be technical and clinical rather than simply additional publicity about fundraising. They include a prototype demonstration, peer-reviewed performance data, disclosure of a specific clinical use case, clinical collaborations, customer or laboratory pilots, regulatory filings, and evidence that the system can reduce total workflow cost while maintaining clinical-grade performance.
Adaptive’s continuing role will also matter. It could remain a parent and strategic partner, become a customer or distribution partner, or eventually change its ownership position. For now, the filings show a business with separate financing but continuing financial and governance ties to Adaptive.
Why the financing matters
Adaptive’s 2025 results reported $277 million in total annual revenue, with MRD accounting for most of the business. Against that backdrop, Digital Biotechnologies is a small, early-stage adjacent venture rather than the center of Adaptive’s current commercial model. The financing gives the project a way to pursue a potentially broader sequencing opportunity without confusing it with Adaptive’s established MRD business.
For biotechnology and venture readers, the key signal is organizational: Adaptive is preserving exposure to a sequencing platform while bringing in separate capital and moving some operating responsibility outside the parent. Whether that structure creates value will depend on technical performance, regulatory progress, clinical adoption, and the company’s ability to operate with less support from Adaptive.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
